Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

LGC

LGC : 15 May, 2006  (Company News)
LGC, Europe
LGC, Europe´s leading independent analytical laboratory providing advanced chemical, biochemical and forensic analysis will be launching its new screening service of the genes associated with non-polyposis colorectal cancer with a stand at the First Conference of International Society for Gastrointestinal Hereditary Tumours, at the Hilton Newcastle Gateshead, 14 - 17 June 2005. LGC is also the primary sponsor of the UK Cancer Genetics Group meeting, a satellite meeting which will run alongside the conference on 14 June.

The new service, which will be offered to European as well as NHS customers, is the screening of the DNA mismatch repair genes hMLH1, hMSH2 and hMSH6 for variations that may be associated with HNPCC. Developed and validated in a series of blind trials with collaborator groups within and outside the NHS, including three separate colon cancer centres and the Life Knowledge Park in Newcastle, LGC´s colon cancer screening service provides the assignation and reporting of exact mutations and positions and detection of single nucleotide variants. It is an ISO 17025 and IVDD compliant service and promises rapid turnaround times to meet the individual referrer´s requirements.

Dr Paul Debenham, Director of Life Sciences at LGC, said: 'The detection of inherited mutations in certain key genes linked to cancers can provide both diagnostic information about the disease in specific patients, and also enable predictive screening of family members. Using mass spectrometry combined with LGC´s proprietary analysis software, we are now able to rapidly detect exact changes in the DNA of a given patient, and simultaneously characterise the gene mutation with base change and position assigned in one single step.' He added:'We are also able to analyse considerable additional DNA sequences adjacent to the actual coding DNA so as to provide a more comprehensive sweep of the gene information. We are therefore delighted to be at the First Conference of InSiGHT to launch this reliable, rapid and cost-effective gene sequence screening service.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 NewMaterials.com
Netgains Logo